Barnetson, R.S.C., Ooi, T.K.T., Zhuang, L., Halliday, G.M., Reid, C.M., Walker, P.C., Humphrey, S.M., Kleinig, M.J., [Nle 4-D-Phe 7]-α-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned caucasian volunteers (2006) Journal of Investigative Dermatology, 126 (8), pp. 1869-1878. , DOI 10.1038/sj.jid.5700317, PII 5700317
FitzGerald, L.M., Fryer, J.L., Dwyer, T., Humphrey, S.M., Effect of MELANOTAN®, [Nle 4, D-Phe 7]-α- MSH, on melanin synthesis in humans with MC1R variant alleles (2006) Peptides, 27 (2), pp. 388-394. , DOI 10.1016/j.peptides.2004.12.038, PII S0196978105004511, The Melanocortin Pathway 2005 Part II
Hadley, M.E., Dorr, R.T., Melanocortin peptide therapeutics: Historic milestones, clinical studies, and commercialization (2006) Peptides, 27, pp. 921-930
Raposinho, P.D., Xavier, C., Correia, J.D., Melanoma targeting with alpha-melanocyte stimulating hormone analogs labeled with fac-[99mTc(CO)3]+: Effect of cyclization on tumor-seeking properties (2008) J Biol Inorg Chem, 13, pp. 449-459
Evans-Brown, M., Dawson, R.T., Chandler, M., McVeigh, J., Use of melanotan i and II in the general population (2009) BMJ, 338, pp. b566
Langan, E.A., Ramlogan, D., Jamieson, L.A., Rhodes, L.E., Change in moles linked to use of unlicensed 'sun tan jab' (2009) BMJ, 338, pp. b277
Cousen, P., Colver, G., Helbling, I., Eruptive melanocytic naevi following melanotan injection (2009) Br J Dermatol, 161, pp. 707-708
Ellis, R., Kirkham, N., Seukeran, D., Malignant melanoma in a user of melanotan i [E-Letter publication] (2009) Br Med J, , http://www.bmj.com/cgi/eletters/338/feb17_2/b566#209418, Available at
Langan, E.A., Nie, Z., Rhodes, L.E., Melanotropic peptides: More than just 'Barbie drugs' and 'sun-tan jabs'? (2010) Br J Dermatol, 163, pp. 451-455
